Introduction:
Apoptosis or programmed cell death plays an important role in a wide variety of physiological processes. The mechanism of this process is highly conserved throughout all eukaryotic cells 1, 2 . The Bcl-2 family of proteins are central regulators of apoptotic death consisting of both anti -apoptotic (Bcl-2, BclX L , Mcl-1 and A1/Bfl-1) and pro-apoptotic (BclX S , Bax, Bak and Bok/Mtd) factors 3, 4 . The ability of many Bcl-2 family members to form homo-as well as heterodimers through their Bcl-2 homology (BH) domains is important for activation of specific functions such as causing changes in mitochondrial membrane potential and initiating the process of apoptosis, and also for neutralizing these functions in the cells 2, 5, 6 . Most pro-survival factors, which can inhibit apoptosis in response to a wide variety of cytotoxic damages, contain BH1, BH2 and BH3 domains and those most similar to Bcl-2 have all four BH domains 2 . It is thought that the relative ratio of anti-apoptotic versus pro-apoptotic dimers plays a pivotal role in determining the resistance of a cell to apoptosis.
The biochemical events leading to apoptosis in mast cells, which are the major cellular players in allergy, have recently started to be explored. The number of mast cells in tissues has been found to be constant under normal conditions, which probably reflects an equilibrium between cell proliferation, migration and death 7 . The involvement of the Bcl-2 family proteins in human mast cell survival was indicated by the observation that stem cell factor induced elevation of Bcl-2 and BclX L in these cells 7 . Several studies on mast cell leukemia show overexpressed levels of Bcl-2, pointing out the importance of this antiapoptotic protein in mast cell homeostasis 8 .
Other experiments reveal that upon stimulation via the aggregation of high-affinity IgE receptors (Fc RI), mouse mast cells synthesize the anti-apoptotic component A1 rather than Bcl-2 9 . However, it is still uncertain whether A1 plays a direct role in mediating cell 4 survival in these cells. Later it was found that only monomeric IgE binding to its mast cell high-affinity receptor (Fc RI) suppresses the apoptosis induced after growth factor deprivation 10 . This induction of mast cell survival was observed without detectable changes in the expression of other members of the Bcl-2 family of proteins. Thus, from all the data mentioned above it remains unclear whether Bcl-2 is indeed involved in promoting mast cell survival.
In the present work we addressed this topic by using human semi-synthetic phage display antibody library 11 . Phage display libraries of peptides have been used since mid 1980 as a highly effective method for selection of interacting partners 12 . The display of antibody fragments as single-chains Fv (scFv) on phage and the subsequent antigen driven selection has provided a new way for the development of human monoclonal antibodies with potential therapeutic applications 13 .
After selection against recombinant Bcl-2, specific anti-Bcl-2-scFv was isolated and modified by genetic engineering. Moreover, we have found that anti-Bcl-2-scFv linked to TAT peptide sequence penetrates living cells, binds specifically to Bcl-2 at a region including BH1 domain and eradicates the anti-apoptotic activity of the cellular protein in two types of mast cells and in a human breast cancer cell line.
Materials and Methods:
Cell culture:
Rat basophilic leukemia (RBL) and breast cancer (MCF7) cells were maintained in RPMI-1640 medium (Invitrogen Corporation, Carlsbad, CA) supplemented with 10%
FCS, 2 mM L-Glutamine, antibiotic mix (100 units/ml penicillin, 100 µg/ml streptomycin), 2 mM nonessential amino-acids (Biological Industries, Israel), and 50 µM -mercaptoethanol (Fisher Science, Medford, MA). Femoral bone marrow cells derived from wild-type mice (C57BL/6) were cultured in IL-3-containing medium for 3 weeks to generate bone marrow derived mast cells (BMMC) as previously described 14 . All the cells were grown in a humidified incubator at 37 o C with 5% CO 2 .
Purification of bacterially expressed GST proteins:
GST-Bcl-2 ( C21) was expressed from pGEX-Bcl-2 (a kind gift of Dr. A. 
Selection of scFv against Bcl-2 from phage display library:
We employed human semi-synthetic scFv library constructed from a single human framework for V H (DP-47 and JH4B) and V L (DPK9 and JK1) joined by J K linker, in which diversity was incorporated in CDR3 and CDR2 11 . The screening of the phage display antibody libraries was performed as previously described 15 . Briefly, immunotubes (Nunc-Immuno Tubes, MaxiSorp, Nunc, Denmark) were coated with 10 µg/ml GST-Bcl-2 in PBS and exposed for 2 hours to 10 12 -10 13 transforming units (t.u.) of the phage library.
For enrichment of the GST-Bcl-2-bound phage, E. coli TG-1 was infected with the eluted phages and rescued by the helper phage. The panning process was repeated four times and E. coli TG-1 was infected with the final phage preparations and individual ampicillin-resistant colonies (phage clones) were selected for further analysis.
Screening and sequencing of Bcl-2-specific phage clones:
Screening for positive anti-Bcl-2 phage clones were first done by ELISA, as previously described 16 . Microtiter plate (Nunc) wells were coated with antigen by adding to each well 100 µl of GST-Bcl-2 (10 µg/ml in PBS) using GST as negative control and incubated with 100 µl of phage suspension for 90 min. After removal of the supernatants, the amount of bound phage was determined using peroxidase-labeled anti-M13 antibodies The entire scFv DNA fragment of the selected phage clones with specific anti-Bcl-2 activity was sequenced using the primers, LMB-3 (5'-C AGGAAACAGCTATGAC) and Fd-
Seq (5'-GAATTTTCTGTATGAGG).

Production and purification of anti-Bcl-2-scFv:
The Bcl-2-reactive phage clones obtained from E.coli TG-1 bacteria were used to infect E. coli HB2151 non-suppressor bacterial strain to obtain soluble scFv 15 . After overnight induction with 1 mM IPTG at 30 o C, the antibody fragments derived from the V H 3 family were harvested from the supernatant and periplasmic space as described 15 16 (Zymed Laboratories, San Francisco, CA).
Membrane translocation of scFvs-TAT:
RBL and MCF7 cells were grown on cover slips coated with collagen in 6-wells plates In vitro protein interaction assay: equipped with an argon ion laser emitting at 488 nm, in FL2 channel.
Cell death assay:
BMMC (1x10 4 ) were cultured in 96-well round-bottom plates (Nunc) and RBL (5x10 3 ) in 96-well flat-bottom plates (Nunc) in 0.15 ml of cultured medium supplemented with either anti-Bcl-2-scFv-TAT or non-specific -scFv-TAT at different concentrations.
Cell viability was determined by trypan blue exclusion following 24, 36, 48 and 72 hours in culture.
Apoptosis assay:
RBL and MCF7 cells were cultured on cover slips coated with collagen in 6-well plates (4x10 5 cells/well) in 2 ml RPMI containing 10% FCS for 24 hours at 37 o C, 5% CO 2 .
After treatement with 30 µg/ml of the different scFv-TAT for 72 hours, the apoptotic cells were determined by using DeadEnd™ Fluorometric TUNEL system (Promega) following the manufacturer's instructions.
Results:
Characterization of the positive phage clones and the construction of anti-Bcl-2-scFv-TAT:
Following four rounds of selection using human semi-synthetic phage display antibody library, several positive clones were isolated. Clones were considered positive only if they did not bind to negative GST control and showed an O.D. 450 nm of at least three-fold over the background (Fig. 1A) .
Three positive scFv clones were used to infect non-supressive E. coli HB1251 bacteria to obtain soluble expression of the selected scFv. Only one positive clone (A9) was chosen, after it was assessed against GST-Bcl-2 and native Bcl-2 from different lysates (data not shown). We then added TAT sequence (YGRKKRQRRR) 17 , which is responsible for translocation through the membrane, to the positive clone (A9) and to the negative clone, which did not show any specificity against either Bcl-2 or GST. After verifiying the sequence (Fig. 1B) , vectors containing the recombinant antibodies were further transformed into competent E.coli bacteria, induced with IPTG and the proteins were purified on affinity columns. This procedure enabled us to obtain large scale amounts of different scFv-TATs (~4 mg protein per liter culture). The integrity of the recombinant antibodies was assessed by Western blotting and identified with Protein A-HRP, as shown in Fig. 1C . 
Translocation of anti-Bcl-2-scFv-TAT into cells:
The penetration of the anti-Bcl-2-scFv-TAT into living cells was assessed using immunofluorescence. RBL and MCF7 cells were grown on collagen -coated cover slips and incubated with 10 µg/ml for 90 min at 37 o C with anti-Bcl-2-scFv-TAT, anti-Bcl-2-scFv (without TAT) and non-specific-scFv-TAT as controls. Fig. 2 shows the translocation of anti-Bcl-2-scFv-TAT into RBL cells (Figs. 2C, 2D) . Moreover, the internalization follows a dose-dependent curve as observed by the intensity of the recorded signals (Figs. 2C, 2D ). The translocation of the control non-specific-scFv-TAT through the cell membrane was also verified (data not shown). In contrast, cells treated with anti-Bcl-2-scFv alone did not display such fluorescent signals (Fig. 2B) .
Similar results were obtained using MCF7 cells (data not shown).
These results strongly suggest that the gain in fluorescence in the different scFv-TATtreated cells reflects the membrane-translocating activity of the recombinant antibodies. RBL cells (untreated, (A)) were exposed for 90 min to anti-Bcl-2-scFv-TAT at different concentrations (5 µg/ml (C), 15 µg/ml (D)), and to 10 µg/ml anti-Bcl-2-scFv (B). The translocation of anti-Bcl-2-scFv-TAT into the cell cytoplasm was visualized using ProteinA-FITC, seen here as white dots. Cells were observed under a fluorescent microscope at 40 x magnification.
The involvement of the BH1 domain of Bcl-2 in the interaction with anti-Bcl-2-scFv-TAT:
After testing antigen recognition and TAT-mediated translocation into the cells, we next assayed the in vivo ability of anti-Bcl-2-scFv-TAT to bind intracellular Bcl-2. After incubation of RBL cells with anti-Bcl-2-scFv-TAT or with the control non-specific -scFv-TAT, the proteins were immunoprecipitated with commercial anti-Bcl-2 bound to Protein A-agarose. The presence of the anti-Bcl-2-scFv-TAT in the cells was detected by Western blot analysis using anti-myc antibodies 15 against the myc epitope on the scFv. Fig. 3A demonstrates that only the anti-Bcl-2-scFv-TAT is bound to the native Bcl-2.
Pull down assay was carried out in order to identify the domain(s) of Bcl2 that is responsible for the interaction with anti-Bcl-2-scFv-TAT. PCR fragments coding for regions including the various BH-Bcl-2 domains were used for the assay. Since the different BH domains were very short, we amplified larger, specific Bcl-2 fragments, containing these domains, as shown in the multiple sequence alignment (Fig. 3B) . AntiBcl-2-scFv-TAT was expressed in bacteria, immobilized on Protein A-agarose beads, and assayed for its ability to retain the in vitro translated Bcl-2 and its BH domains labeled domain binds to anti-Bcl-2-scFv-TAT (Fig. 3C) . In contrast, the other BH domains did not bind to anti-Bcl-2-scFv-TAT. The anti-Bcl-2-scFv-TAT also interacted with the fulllength of Bcl-2 (data not shown). A. Binding of anti-Bcl-2-scFv-TAT to intracellular Bcl-2. Bcl-2 was immunoprecipitated from RBL cells with anti -Bcl-2 immobilized on ProteinA-agarose. The binding of anti-Bcl-2-scFv-TAT (lane 1) or non-specific scFv-TAT (lane 2) to intracellular Bcl-2 was determined by Western blot analysis using antibody against the myc tag on the scFv.
B. The sequence of the Bcl-2-BH domains and their homology to other BH domains in
the Bcl-2-family proteins. The box encloses the BH domains and the Bcl-2 sequences before and after the box complete the fragments for PCR. 
The specificity of the anti-Bcl-2-scFv-TAT :
The specific binding of anti-Bcl-2-scFv-TAT to Bcl-2 rather than to the other antiapoptotic Bcl-2 family proteins was then determined. For this purpose, the proteins Bcl-2, BclX L , A1 and Mcl-1 were immunoprecipitated from RBL cell lysates using their specific antibodies and then identified by the same antibodies (Fig. 4 upper pannel) . The specificity of the anti-Bcl-2-scFv-TAT wa s determined by Western blotting using the same blots (Fig.   4 lower pannel) . As shown , the band corresponding to the purified Bcl-2 from the cell lysate was specifically identified by anti-Bcl-2-scFv-TAT. As control, we used GST-Bcl2, which was detected by anti-Bcl-2-scFv-TAT (data not shown). None of the other antiapoptotic proteins were recognized by anti-Bcl-2-scFv-TAT.
Fig. 4: Anti-Bcl-2-scFv -TAT is a Bcl-2-specific antibody.
The various anti-apoptotic Bcl-2-family proteins were immunoprecipitated (IP) using their specific antibodies. Each immunoprecipitated protein was first identified by Western bloting (WB) with its specific antibody (upper pannel). The same immunoblot was probed with anti-Bcl-2-scFv-TAT and Protein A-HRP as secondary antibody (lower pannel). One representative out of three experiments is shown.
The effect of anti-Bcl-2-scFv-TAT on the mitochondrial membrane potential:
For further characterization of the mechanism involved in the inhibition of the Bcl-2 function by anti-Bcl-2-scFv-TAT, changes in the mitochondrial membrane potential ( m )
were monitored following cell treatement with 30 µg/ml of thedifferent scFvs-TAT and at various intervals of time. The analysis was performed by observing the accumulation of the fluorescent dye MitoTracker Red in the cell mitochondria. Fig. 5 shows the specific effect of the anti-Bcl-2-scFv-TAT on m of the cells, as can be noticed by the decrease in the fluorescence after 12 hours (Fig. 5A , lower pannel) in comparison to the 1 h treatement (Fig. 5A, upper pannel) . In contrast, the non-specific-scFv -TAT did not cause to any decrease in the fluorescence as represented at the different points of time (Fig. 5B) . 
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The effect of anti-Bcl-2-scFv-TAT on cell survival:
BMMC and RBL cells were incubated for 72 hours and 36 hours respectively with anti-Bcl-2-scFv-TAT or with the control non-specific -scFv-TAT, and cell survival was tested by trypan blue exclusion and cell counting (Fig. 6 ).
The viability of the BMMC cells decreased with increasing anti-Bcl-2-scFv-TAT concentrations. BMMC treated with non-specific-scFv-TAT showed a similar percentage viability as observed for untreated BMMC (Fig. 6A) . The same assay was also carried out in RBL cells. A significant decrease in cell viability was shown only in those cells treated with anti-Bcl-2-scFv-TAT (Fig. 6B) . 
Anti-Bcl-2-scFv-TAT-induced apoptosis:
The possible induction of apoptosis by anti-Bcl-2-scFv-TAT was examined in RBL ( 
Anti-Bcl-2-scFv-TAT affects the level of Bcl-2 and its interaction with Bax:
The observations that anti -Bcl-2-scFv-TAT directly binds to Bcl-2 and induces cell apoptosis via its effect on the mitochondrial membrane potential were further analysed by determining the protein level of Bcl-2 in RBL cells treated for various periods of time with either the specific or the non-specific antibody (Fig. 8) . In contrast with cells exposed to non-specific-scFv-TAT which show a constant level of Bcl-2 throughout twelve hours, the level of Bcl-2 significantly decreased in cells treated with anti-Bcl-2-scFv-TAT (Fig. 8 first row). Moreover, the interaction of Bcl-2 with the Bax protein was increased with time only in the cells treated with the specific antibody ( Fig. 8 second row) . The presence of scFv-TAT was identified only in the cells treated with anti-Bcl-2-scFv-TAT ( Fig. 8 third row). Anti-actin was used as a loading control ( Fig. 8 fourth row) . The level of Bcl-2 protein was analysed in RBL cells treated for various periods of time with either anti-Bcl-2-scFv-TAT or non-specific -scFv-TAT. After immunoprecipitation with anti-Bcl-2 antibody , Bcl-2 was identified by Western blotting (first row) . The same immunoblot was exposed to anti-Bax antibody in order to determine the interaction between Bcl-2 and Bax (second row). The presence of scFv-TAT was visualised using anti-myc antibody (third row). Antiactin was used as a loading control (fourth row).
Discussion:
In this study, we have described a novel approach that allows the efficient delivery of single chain antibodies into several types of living cells and thus modulates the proteinprotein interaction of the anti-apoptotic Bcl-2 protein.
The developments in antibody engineering and recombinant DNA technology have made it possible to generate recombinant antibodies with a high degree of specificity and affinity for any antigens by employing phage display technology and constructing very large repertoires of antibodies that are displayed on the surface of filamentous phage 18, 19 .
The use of single chain antibodies enables the use of smaller molecules than regular antibodies, which are simpler to introduce into cells. Two mRNA degradation strategies, RNAi and antisense RNA are now available for the study of the function of specific genes.
However, these two approaches are useful especially against short-lived proteins and therefore are not a hundred percent effective for other molecules. The advantage of using single chains is their ability to adopt three-dimensional conformations and to homodimerize as whole antibodies, in this way mimicking the immune system. This feature makes single chain antibodies attractive not only for research, but also for gene therapy. One approach is loading the cells with dominant-negative proteins, so the native protein is in competition with its dominant-negative form and the cell is under stress.
When using single chain antibodies, the cell is able to continue its cycle until a definite point since the recombinant antibody neutralizes the native protein successively and noncompetitively. The use of proteins has a further advantage that in the future, genetic engineering could be employed to express intracellularly the antibody, so allowing homing to specific cellular compartments, without the need for conjugation of peptides to oligonucleotides or specific drugs.
As we show in this study, the single-chain Fv selected from the phage display library was raised specifically against Bcl-2 and its intracellular uptake was totally dependent on the basic residues of TAT signal sequence. Several studies have recently showed that TAT protein is able to induce apoptosis in several types of cells 20 . However, we used only the fragment of TAT that is responsible for protein translocation and the control scFv conjugated to TAT did not increase cell death as compared to untreated cells. These results also support the notion that the antibody not only bound intracellularly to Bcl-2, but also inhibited the activity of this anti-apoptotic protein. It thus seems that TAT transport of a single chain can deliver a biologically active antibody into cells.
The mechanism of translocation of the TAT basic peptide could be analogous to the model proposed for the Antennapedia homeodomain peptide 21 . A tight ionic interaction between the basic groups of the peptide side chains and the negative charges of the phospholipid heads could induce a local invagination of the plasma membrane. The local reorganization of the phospholipid bilayer would then lead to the formation of inverted micelles with the protein enclosed in the hydrophilic cavity and ultimately to the cytoplasmic release of the scFv-TAT. 22 .
Since a nuclear localization sequence is present in TAT peptide, we expected to find the recombinant antibody also in the nucleus. However, the high affinity of anti-Bcl-2-scFv-TAT for its cellular target leads to the binding of the antibody fragment to Bcl-2 and its localization in cytosol alone.
Bcl-2 is a cytoplasmic protein mainly anchored in the outside mitochondrial membrane and in the outside membrane of the nucleus. Confocal microscopy showed cytoplasmic distribution of the recombinant antibody and absence of nuclear staining.
Thus, we attribute the biological activity to the scFv that was carried inside the cell by TAT. Moreover, our results from the co-immunoprecipitation showed the binding of the specific single chain to native Bcl-2, indicating the high affinity and specificity of the novel anti-Bcl-2-scFv-TAT, whereas the control antibody was detected inside the cells, however not bound to Bcl-2.
Previous mutagenesis and deletion analyses of Bcl-2 family members have concentrated primarily on the regions of homology: BH1, BH2 and BH3. These domains have shown to be involved in mediating dimerization between the various family members 23, 24 . Using domain mapping studies, we demonstrated that the amino acids 136-155, containing the Bcl-2-BH1 domain, are responsible for binding of the anti-Bcl-2-scFv-TAT.
Both BH1 and BH2 domains are required for the inhibition of apoptosis since heterodimerization of Bcl-2 with Bax, by through these two domains leads to apoptosis 23 .
Consistent In addition, the use of Bcl-2 overexpressing-breast cancer MCF7 cells 25 underlines the efficiency of anti-Bcl-2-scFv-TAT in neutralizing Bcl-2, so leading to cell apoptosis.
Moreover, the results of the proliferation assay emphasize the importance of Bcl-2 in mast cell survival. The effect of the anti-Bcl-2-scFV-TAT was greater in transformed mast cells (RBL) than in the primary culture of BMMC. This observation indicates that IL-3, the growth factor added to the medium, may antagonize the effect of anti-Bcl-2-scFv-TAT by upregulating Bcl-2 level in the cells.
The mechanisms by which Bcl-2 regulates apoptosis in mast cells are poorly understood. In a recent study, a significant decrease in the survival of gastric mucosal mast cells derived from Bcl-2 -/-mice was observed, whereas in Bax-/-mice an increase in the survival of these cells was seen 26 . Thus, Bcl-2 probably also plays an important role in the survival in vivo of mucosal mast cells, which share many features with BMMC. The normal number of skin mast cells observed in that study could be explained by different survival factors secreted in the skin environment. Altogether, the results from the study of Maurer and our study suggest that Bcl-2 plays an important role in mast cell survival under certain circumstances.
Our results support the claim that Bcl-2 has a major role in mast cell survival 7 . It seems that anti-Bcl-2-scFv-TAT triggers apoptosis through a mechanism that involves direct targeting of Bcl-2 on the mitochondria. Further studies are needed to demonstrate whether inhibition of Bcl-2 also effects mast cell survival in vivo.
Inhibiting the function of intracellular proteins is an important goal for anyone studying the role of a specific protein in biochemical pathways and for those who try to develop specific therapeutic substances. The in vitro biological activity of anti-Bcl-2-scFv -TAT should be widely applicable to the study of diverse biological questions and makes it attractive for clinical applications.
